Toxic Exposures Clinical Trial Award
ID: 355156Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/355156
Timeline
    Description

    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Fiscal Year 2024 (FY24) Toxic Exposures Clinical Trial Award (CTA) to support clinical trials focused on military-related toxic exposures. This funding opportunity aims to facilitate research that addresses the prevention, diagnosis, treatment, and underlying mechanisms of health issues stemming from such exposures, with applicants required to align their proposals with at least one FY24 Toxic Exposures Research Program (TERP) Goal and Topic Area. The initiative is crucial for advancing understanding and management of health consequences related to military service, with a total funding pool of $30 million available, including direct costs capped at $1.5 million for single Principal Investigator (PI) projects and $2.5 million for partnering PI applications. Key deadlines include a pre-application due by August 13, 2024, and a full application by November 7, 2024; interested parties can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.

    Point(s) of Contact
    help@eBRAP.org
    Files
    Title
    Posted
    HT942524TERPCTA-GG.pdf
    The Department of Defense (DOD) is offering the Fiscal Year 2024 (FY24) Toxic Exposures Clinical Trial Award (CTA) through the Toxic Exposures Research Program (TERP) to support research addressing military-related toxic exposures. This funding opportunity is aimed at clinical trials that will investigate prevention, diagnosis, treatment, and the underlying mechanisms of health issues caused by such exposures. Applicants must align their proposals with at least one FY24 TERP Program Goal and Topic Area, which include elucidating toxic exposure mechanisms and developing therapeutics. Key deadlines include a pre-application by August 13, 2024, and a full application by November 7, 2024. The total funding available is $30 million, with direct costs limited to $1.5 million for single PI projects and $2.5 million for partnering PI applications. Eligible applicants include both extramural and intramural organizations, and the application process involves a two-step submission through the Electronic Biomedical Research Application Portal (eBRAP) and Grants.gov. Proposals emphasizing collaborative efforts with the Department of Veterans Affairs and focusing on military health outcomes are encouraged. The initiative underscores a commitment to understanding and addressing health consequences related to military service exposures.
    Similar Opportunities
    Toxic Exposures Translational Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Toxic Exposures Translational Research Award (TRA) to support research on adverse health outcomes related to military toxic exposures. This grant aims to facilitate translational research that bridges basic science and clinical applications, focusing on developing diagnostics, treatment strategies, and understanding exposure mechanisms to improve health care for service members and their families. With an estimated total program funding of $12.8 million and the expectation of awarding six grants, applicants must submit a pre-application by August 13, 2024, followed by a full application due by November 7, 2024. For further inquiries, interested parties can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    Toxic Exposures Investigator-Initiated Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Toxic Exposures Investigator-Initiated Research Award (TERP IIRA) to support research addressing health outcomes related to military-related toxic exposures. This grant aims to fund studies that contribute significantly to understanding and improving patient care for diseases associated with such exposures, encompassing all research phases from basic laboratory studies to translational research involving human subjects and animal models. With an estimated total program funding of $3.2 million and the expectation of awarding four grants, interested applicants must submit pre-applications by August 13, 2024, and full applications by November 7, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DoD Combat Readiness - Medical, Translational Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Combat Readiness - Medical Translational Research Award (CRRP TRA) to support high-impact translational research aimed at enhancing medical readiness for military personnel. This funding opportunity seeks proposals that address critical areas such as battlefield diagnostics, treatments for life-threatening injuries, and operational health threats, with an emphasis on projects that leverage existing resources and demonstrate clear relevance to military health. The total estimated funding for this initiative is approximately $3.3 million, with the expectation of awarding around three grants, and key deadlines include pre-applications due by September 4, 2024, and full proposals by December 5, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    DoD Peer Reviewed Cancer, Advancing Cancer Care Through Clinical Trials Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering a grant opportunity titled "DoD Peer Reviewed Cancer, Advancing Cancer Care Through Clinical Trials Award" for Fiscal Year 2024. This funding initiative aims to support the rapid implementation of clinical trials that have the potential to significantly impact cancer treatment and management, particularly for military personnel and their families, addressing specific topic areas related to military health. With an estimated total program funding of $24 million and the expectation of awarding up to five grants, eligible applicants can submit proposals that demonstrate the feasibility and relevance of their clinical trials, with a maximum award amount of $3 million. Interested parties must submit their applications by October 15, 2024, and can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    DoD Multiple Sclerosis, Clinical Trial Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Multiple Sclerosis Clinical Trial Award to support clinical trials aimed at improving treatment and management of multiple sclerosis (MS). This funding opportunity encourages innovative trials that may include new pharmacologic agents, devices, or emerging technologies, with a total estimated program funding of $8 million and the expectation of awarding three grants. Eligible applicants include unrestricted entities, and the funding levels are set at a maximum of $2 million for small-scale trials and $4 million for larger-scale studies, with a pre-application deadline of June 10, 2024, and a full application deadline of October 7, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    DoD Psychedelic Treatment Research Clinical Trial Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the U.S. Army Medical Research and Development Command (USAMRAA), is offering the Fiscal Year 2024 Psychedelic Treatment Research Clinical Trial Award (PTRCTA) to support clinical trials evaluating treatments for post-traumatic stress disorder (PTSD) and traumatic brain injury (TBI) among U.S. Service Members using specific psychedelic substances. Applicants are required to propose studies that address at least one of the covered conditions and utilize one or more of the eligible psychedelic substances, including MDMA, psilocybin, and ibogaine, with trials ranging from small proof-of-concept studies to larger efficacy trials. With an estimated total program funding of $9.8 million and the expectation of awarding two grants, interested parties must submit pre-applications by September 20, 2024, and full applications by October 4, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DoD Traumatic Brain Injury and Psychological Health, Clinical Trial Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Traumatic Brain Injury and Psychological Health Clinical Trial Award (CTA) to support clinical trials aimed at improving the understanding, prevention, and treatment of traumatic brain injuries (TBI) and psychological health conditions affecting military personnel and veterans. This funding opportunity encourages innovative research methodologies, including Community-Based Participatory Research (CBPR), and requires applicants to demonstrate robust statistical analyses, participant recruitment strategies, and regulatory compliance. With an estimated total program funding of $58.9 million, the CTA anticipates awarding approximately 18 grants across various research levels, with budget caps ranging from $500,000 to $4 million, and key deadlines include a pre-application by June 27, 2024, and a full application by October 3, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DoD Peer Reviewed Orthopaedic, Clinical Trial Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the Congressionally Directed Medical Research Programs (CDMRP), is offering the Fiscal Year 2024 (FY24) Peer Reviewed Orthopaedic Clinical Trial Award aimed at enhancing recovery from combat-related orthopaedic injuries. This grant supports clinical trials that focus on innovative treatment strategies, including limb stabilization, battlefield care, and rehabilitation, with an emphasis on interdisciplinary collaboration to improve military readiness and patient care. With an estimated total program funding of $13.25 million, the program anticipates awarding up to four grants of $2.5 million each for standard projects and one grant of $3.25 million for collaborative care projects. Interested applicants must submit pre-applications by June 18, 2024, and full applications by September 17, 2024; for further inquiries, contact the CDMRP Help Desk at help@eBRAP.org.
    DoD Peer Reviewed Orthopaedic, Clinical Translational Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the U.S. Army Medical Research and Materiel Command (USAMRAA), is offering the Fiscal Year 2024 Peer Reviewed Orthopaedic Clinical Translational Research Award (CTRA) to support innovative research aimed at addressing significant gaps in orthopaedic care, particularly for military personnel with combat-related injuries. This funding opportunity encourages proposals that focus on enhancing treatment options and rehabilitation strategies for orthopaedic injuries, with an emphasis on interdisciplinary collaboration and clinical relevance. The total estimated funding for this program is $6 million, with a maximum award amount of $1.5 million per project, and applications are due by September 17, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    CDMRP Neurofibromatosis Clinical Trial Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the Congressionally Directed Medical Research Programs (CDMRP), is offering the Fiscal Year 2024 Neurofibromatosis Clinical Trial Award to support innovative clinical trials aimed at addressing high-impact issues related to neurofibromatosis (NF), including NF1, NF2, and schwannomatosis. Applicants are required to present a clear clinical trial design, preliminary data, and access to suitable patient populations, with a focus on enhancing understanding, diagnosis, and treatment of NF to benefit service members, veterans, and the public. This funding opportunity, totaling approximately $1.6 million for the award, encourages collaborative proposals involving academia, industry, and military branches, with key deadlines for pre-applications on September 12, 2024, and full applications by October 3, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.